Mobocertinib (TAS-120) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC). It is an orally administered tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR) gene mutation known as T790M. It works by blocking the activity of the T790M mutation, which is often responsible for resistance to other EGFR inhibitors. Mobocertinib is indicated for the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC who have progressed on or after EGFR TKI therapy.
Mobocertinib is a relatively new targeted therapy medication showing promise in treating specific types of lung cancer. Here's a breakdown of its key features:
Function:
- Mobocertinib works by inhibiting a specific protein called EGFR (epidermal growth factor receptor). EGFR plays a crucial role in the growth and division of some cancer cells.
- By blocking EGFR, Mobocertinib can help slow down or stop the growth of these cancer cells.
Applications:
- Mobocertinib is currently approved for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC). NSCLC is the most common type of lung cancer.
- It's specifically indicated for patients whose cancer has a mutation in exon 20 of the EGFR gene. This mutation is found in a subset of NSCLC cases.
- Mobocertinib is typically used when other targeted therapies haven't been successful.
Administration:
- Mobocertinib comes as tablets taken orally, once daily with or without food.
Important Considerations:
- Mobocertinib is a relatively new medication, and long-term effects are still being studied.
- Common side effects can include diarrhea, rash, fatigue, mouth sores, and dry skin.
- More serious side effects like interstitial lung disease (inflammation of the lungs) can also occur.
- Mobocertinib can interact with other medications, so it's vital to inform your doctor about all medications you're taking before starting treatment.
- Due to potential birth defects, it's not recommended for pregnant or breastfeeding women.